Posted Mar. 20, 2017 at 2:07 p.m.

Premium Lock Novan reports fourth-quarter loss, details steps toward FDA approval of drugs

Published: 2017-03-20 14:07:58
Updated: 2017-03-20 14:07:58

Novan Novan

‚ÄčNovan Inc., a clinical-stage dermatology drug developer, reported a fourth-quarter loss that was better than analysts expected but reported higher drug development expenses, according to a Form 8-K filed Monday with the Securities and Exchange Commission Monday....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 The University of North Carolina at Chapel Hill. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders